Log In
Print this Print this

bertilimumab (CAT-213, iCo-008)

  Manage Alerts
Collapse Summary General Information
Company iCo Therapeutics Inc.
DescriptionHuman mAb against eotaxin-1
Molecular Target Chemokine CC motif ligand 11 (CCL11)
Mechanism of ActionEotaxin-1 inhibitor
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today